Brief: Seelos Therapeutics Receives Positive EMA Opinion On Orphan Drug Designation For SLS-005 In Amyotrophic Lateral Sclerosis
20/04/2021 12:09
April 20 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS RECEIVES POSITIVE EMA OPINION ON
ORPHAN DRUG
DESIGNATION FOR SLS-005 (TREHALOSE) IN AMYOTROPHIC LATERAL
SCLEROSIS (ALS)
Source text for Eikon: ID:nPn3qlrm5a
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio